This 2011 study from the Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) compared radical prostatectomy to watchful waiting in 695 men with early-stage prostate cancer over a median follow-up of 12.8 years. The findings indicated that radical prostatectomy significantly reduced prostate cancer-specific mortality (14.6% vs. 20.7% at 15 years;
This randomized controlled trial examined long-term quality-of-life outcomes in 400 Swedish and Finnish men with localized prostate cancer randomized to either radical prostatectomy or watchful waiting, with a median follow-up of 12.2 years. Self-assessed high quality of life was reported by 35% in the prostatectomy group, 34% in the watchful
This review article examines the management of localized prostate cancer, highlighting watchful waiting, radical prostatectomy, and radiation therapy as primary treatment options. It emphasizes that prostate cancer often progresses slowly, particularly in men over 65, making active surveillance a viable option for many patients. The choice of treatment should be
This randomized controlled trial followed 695 men with clinically localized prostate cancer over a median of 23.2 years, comparing radical prostatectomy to watchful waiting. The study found that radical prostatectomy significantly reduced prostate cancer-specific mortality (relative risk 0.55; 95% CI, 0.41–0.74; P7) and extracapsular extension significantly increased prostate cancer mortality
This randomized controlled trial compared radical prostatectomy (RP) with watchful waiting (WW) in 695 men with early prostate cancer over a median follow-up of 12 years, assessing symptom burden, androgen deprivation therapy (ADT) use, and quality of life (QoL). RP was associated with lower prostate cancer-specific mortality but higher rates
